Carlo Selmi

Education

• 2002: PhD in Internal Medicine, University of Milan, Italy
• 1998: MD, University of Milan, Italy

Academic Appointments

• 2019 – present: Associate Professor of Internal Medicine, Humanitas University, Milan, Italy
• 2011 – 2019: Assistant Professor / Researcher in Rheumatology, University of Milan, Italy
• 2006 – 2014: Assistant Adjunct Professor of Medicine, Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis School of Medicine, USA
• 2006: Appointed Assistant Professor of Internal Medicine, University of Milan, Italy
• 2001 – 2004: Post-doctoral Researcher, Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis School of Medicine, USA

Awards and Honors

• 2004: Young Researcher Prize, Italian Society of Internal Medicine
• 2005: Young Investigator Award, Aesku-Kipp Foundation

Carlo Selmi currently leads the Rheumatology and Clinical Immunology Unit at Humanitas research hospital. At Humanitas he leads a young group of physician scientists with wide research and clinical expertise, including periods working at foreign institutions. The team holds dedicated clinics for rheumatoid arthritis, spondiloarthritis, connective tissue disease with dedicated clinics for systemic sclerosis and systemic lupus erythematosus, and is active in articular ultrasound, videocapillaroscopy, arthrocenthesis and intra-articular injections. He has coauthored over 300 peer-reviewed publications with a Scopus H index of 55 and a total impact factor exceeding 2000.

His research track is dedicated to organ-specific and systemic autoimmune and chronic inflammatory diseases, including the clinical epidemiology and pathogenetic mechanisms of autoimmune liver disease, connective tissue disease (particularly systemic sclerosis), and psoriatic arthritis. His work has been funded by the National Institutes of Health, American Liver Foundation, American Scleroderma Foundation, Italian Ministry of Health, Italian Ministry of Foreign Affairs, and the Lilly Research Foundation.

1. SELMI C., Ceribelli A., Generali E., Scirè C.A., Alborghetti F., Colloredo G., Porrati L., Achenza M.I., De Santis M., Cavaciocchi F., Massarotti M., Isailovic N., Paleari V., Invernizzi P., Matthias T., Zucchi A., Meroni P.L. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev. 2016.
2. Generali E., Ceribelli A., Stazi M.A., SELMI C. Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun. 2017
3. Favalli E.G., SELMI C., Becciolini A., Biggioggero M., Ariani A., Santilli D., Fusaro E., Parisi S., Massarotti M., Marchesoni A., Meroni P.L. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: A multi-center retrospective analysis. Arthritis Care Res (Hoboken).
4. Rizzetto L, Fava F, Tuohy KM, SELMI C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex. J Autoimmun. 2018
5. Generali E, Carrara G, Kallikourdis M, Condorelli G, Bortoluzzi A, Scirè CA, SELMI C. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int. 2019